Marker Therapeutics, Inc. (NASDAQ:MRKR) Given Average Recommendation of “Buy” by Analysts

Shares of Marker Therapeutics, Inc. (NASDAQ:MRKR) have been assigned an average recommendation of “Buy” from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $10.1667.

Several equities analysts have recently issued reports on MRKR shares. Wall Street Zen downgraded shares of Marker Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, November 30th. HC Wainwright started coverage on shares of Marker Therapeutics in a research report on Monday, December 8th. They issued a “buy” rating and a $10.00 price objective on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Wednesday, October 8th. Zacks Research upgraded shares of Marker Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, November 18th. Finally, UBS Group reaffirmed a “buy” rating on shares of Marker Therapeutics in a report on Monday, December 8th.

Marker Therapeutics Trading Up 3.5%

Shares of Marker Therapeutics stock opened at $1.47 on Monday. The stock has a market capitalization of $24.50 million, a price-to-earnings ratio of -1.20 and a beta of 1.35. Marker Therapeutics has a twelve month low of $0.81 and a twelve month high of $5.95. The business’s 50 day simple moving average is $1.09 and its 200-day simple moving average is $1.22.

Marker Therapeutics (NASDAQ:MRKR) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.12) EPS for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.57. Marker Therapeutics had a negative return on equity of 92.35% and a negative net margin of 304.56%.The firm had revenue of $1.23 million during the quarter, compared to the consensus estimate of $0.72 million. Sell-side analysts predict that Marker Therapeutics will post -0.65 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of Marker Therapeutics during the third quarter valued at $25,000. Two Sigma Investments LP acquired a new stake in Marker Therapeutics in the third quarter worth about $33,000. Finally, Jane Street Group LLC bought a new position in Marker Therapeutics in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 22.39% of the company’s stock.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens.